Journal Article

56O_PRPREDICTIVE VALUE OF AKT/MTOR PATHWAY IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS FOR RESPONSE TO PREOPERATIVE TRASTUZUMAB (T) VS TRASTUZUMAB + EVEROLIMUS (T + E) IN PATIENTS (PTS) WITH EARLY BREAST CANCER (BC): UNICANCER RADHER TRIAL RESULTS

M. Campone, T. Bachelot, X. Paoletti, J. Merlin, S. Delaloge, D. Loussouarn, J. Bonneterre, M. Jimenez, M. Rios and I. Treilleux

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 24, issue suppl_3, pages iii30-iii30
Published in print May 2013 | ISSN: 0923-7534
Published online May 2013 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdt084.4
56O_PRPREDICTIVE VALUE OF AKT/MTOR PATHWAY IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS FOR RESPONSE TO PREOPERATIVE TRASTUZUMAB (T) VS TRASTUZUMAB + EVEROLIMUS (T + E) IN PATIENTS (PTS) WITH EARLY BREAST CANCER (BC): UNICANCER RADHER TRIAL RESULTS

Show Summary Details

Journal Article.  385 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.